---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-275985"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T04:41:30.566231+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eiger BioPharma receives Nasdaq equity deficiency notice; delisting risk elevated

## Summary
- Received Nasdaq deficiency letter on Nov 10, 2023 for failing $10M stockholders' equity requirement.
- Must submit compliance plan by Dec 26, 2023; if accepted, extension to May 8, 2024.
- Also has bid price deficiency (below $1.00) with compliance deadline Jan 22, 2024; likely ineligible for extra extension due to equity shortfall.
- Stock continues trading under EIGR on Nasdaq pending potential delisting appeals.

## SEC filing metadata
- accession: 0001193125-23-275985
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/0001193125-23-275985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/d316543d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-275985
- JSON: https://secwatch.observer/filing/0001193125-23-275985.json
- Plain text: https://secwatch.observer/filing/0001193125-23-275985.txt

## Key facts
- Listing & Compliance Notices
  Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A), 5450(b)
  source text: November 10, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that it no longer satisfies the $10 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(1)(A), or the alternatives to that requirement - a $50 million market value of listed securities or $50 million in net income in the most recent fiscal year or two of the last three fiscal years - as required by Nasdaq Listing Ru
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/0001193125-23-275985-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.